Dynavax Accused Of Duping Investors About Hepatitis Vaccine
Dynavax Technologies Corp. investors hit the biopharmaceutical company with a putative class action Tuesday alleging it made false statements about its Heplisav vaccine for hepatitis B, causing its share price to...To view the full article, register now.
Already a subscriber? Click here to view full article